Overview:
In Uganda alone, frequent FMD outbreaks have resulted in losses amounting to millions annually. Between 2015 and 2019, the country reported 140 outbreaks, with the government spending $176 million on bi-annual vaccination programs
In a groundbreaking achievement, Dr Matthias Magoola, founder and managing director of Dei BioPharma, has secured a US patent for his revolutionary universal vaccine against Foot and Mouth Disease (FMD).
Accepted on January 7, 2025, by the United States Patent and Trademark Office, this vaccine is poised to transform livestock health worldwide, especially in developing nations like Uganda.
Tackling a Global Challenge
FMD, a highly contagious viral disease, affects food-producing animals such as cattle, sheep and goats. While its mortality rate is low, the economic impact on the livestock industry is devastating.
In Uganda alone, frequent FMD outbreaks have resulted in losses amounting to millions annually. Between 2015 and 2019, the country reported 140 outbreaks, with the government spending $176 million on bi-annual vaccination programs. Dr Magoola’s invention, titled “Affordable Universal Fusion Universal Vaccine for Foot and Mouth Disease Infections,” offers a cost-effective and comprehensive solution.
The vaccine’s unique design induces cross-protection against all known serotypes of the FMD virus, minimizing the need for repeated vaccinations. Utilizing advanced mRNA technology, it is both affordable and highly effective. This innovation could save Uganda billions in vaccine imports while creating a model for other developing nations.
As outlined in the documents accompanying his USA patent application, Dr Magoola explains that the vaccine combines epitopes of all known virus strains responsible for FMD. This innovation enables cross-protection against various serotypes and strains, creating what he describes as a “complete universal antigen.”
The technology underpinning Dr Magoola’s vaccine is described as unique in its design and application. According to the patent, the vaccine employs advanced methodologies to enhance its effectiveness and affordability. One notable feature is the fusion of the antigen with serum proteins or synthetic peptides to extend its half-life, making it more durable and efficient.
Additionally, the antigen is linked to an adjuvant using recombinant technology, further boosting its potency. The patent also highlights the use of cutting-edge RNA technology, including linear and circular mRNA, both replicating and non-replicating, to produce the anti-gen. This approach dramatically reduces production costs, making the vaccine accessible globally.
“The innovation brings these vaccines within the affordable reach of the entire world,” the patent reads.
This development represents a major leap forward in combating FMD.
A Visionary’s Global Impact
Dr Magoola’s work extends beyond FMD. Under his leadership, Dei BioPharma has emerged as Uganda’s first research-based biotechnology firm, earning accolades such as the African Excellence Award for Best Pharma Company.
His extensive portfolio includes over 100 USA patents, covering treatments for diseases like malaria, cancer, HIV and Alzheimer’s.
In the fight against malaria, his anti-malarial drug, derived from natural sources, has been lauded as the most efficient of its kind. His Covid-19 vaccine, developed using mRNA technology, exemplifies his ability to respond to urgent global health crises. The US Food and Drug Administration (FDA) has shown significant interest in several of his therapeutic innovations, including a pioneering treatment for acute kidney failure and cancer.
Revolutionizing Medicine with mRNA Technology
Dr Magoola has embraced the potential of mRNA technology, which gained prominence during the Covid-19 pandemic. This cutting-edge approach allows for rapid development and significantly reduces costs, making treatments more accessible.
His patents in neurodegenerative disorders, such as Alzheimer’s, aim to overcome long-standing barriers in drug delivery to the brain. With FDA support, these treatments are anticipated to enter clinical trials in 2025, addressing a global market valued at over $100 billion.
A Legacy of Innovation and Humanitarianism
Beyond his scientific achievements, Dr Magoola has made it his mission to mentor other researchers, sharing technical expertise to foster global medical advancements. His work exemplifies a humanitarian approach to science, ensuring life-saving treatments are affordable and accessible worldwide.
A Bright Future for Dei BioPharma
Dr Magoola’s efforts extend to building a flagship biological drugs and vaccines manufacturing facility in Uganda’s Wakiso district. This development positions Uganda as a leader in pharmaceutical innovation and a key player in global health.
As Uganda and the world face pressing health challenges, Dr Magoola’s dedication to transformative medicine offers hope. His achievements are not just milestones for Uganda but represent a beacon of innovation for the global scientific community